Platelet aggregation and its modulation using antithrombotic agents
Nandini Srivastava, Kaushik Ghanshyambhai Khatrani, Bansari Yagnik Tank, Yagnik Prafulchandra Tank, Urvashi Bachwani, Kevin Ashokbhai Purohit
TL;DR
This study evaluates how three antithrombotic agents affect platelet aggregation, finding that one agent is particularly effective.
Contribution
The study introduces three new antithrombotic agents and identifies one with strong platelet aggregation inhibition.
Findings
AV-303 showed the strongest dose-dependent inhibition of platelet aggregation.
All three agents inhibited platelet aggregation compared to controls (p < 0.05).
The findings suggest potential medical applications for treating thrombotic disorders.
Abstract
Aggregation of platelets using three antithrombotic agents such as Ticagrelor Derivative (TD-101), Rivaroxaban Analog (RA-202) and Apixaban Variant (AV-303) were assessed. All the three agents showed dose-dependent inhibitory effects in platelet aggregation where AV-303 exhibited the strongest inhibitory activity according to light transmission aggregometry. The statistical analysis showed distinctions (p < 0.05) between groups receiving treatment and controls. This opens possibilities for medical applications in thrombotic disorder treatment. It should be noted that additional animal tests and clinical studies are needed to validate effectiveness and safety of these agents.
Genes, proteins, chemicals, diseases, species, mutations and cell lines named across the full text — each resolved to its canonical identifier and authoritative record.
Peer Reviews
No public reviews on file for this paper yet. If you reviewed it on a platform where reviews are public (OpenReview, ICLR, NeurIPS, ICML), you can paste yours below so the community can read it here.
Videos
No videos yet. Explain this paper in a talk, walkthrough, or lecture? Add one.
Taxonomy
TopicsAntiplatelet Therapy and Cardiovascular Diseases